HomeTOP STORIESBoston Scientific ACURATE neo2 aortic valve misses primary endpoint in trial Boston Scientific ACURATE neo2 aortic valve misses primary endpoint in trial By pvadmin October 30, 2024 FacebookTwitterPinterestWhatsApp [#item_full_content] Previous articleThe Eastern Company declares $0.11 dividendNext articleThis is not a Budget we want to repeat, Reeves tells BBC latest articles Westwood holdings outlines ETF growth and new mandates amid Q1 2025 earnings insights First Mid Bancshares Non-GAAP EPS of $0.96 beats by $0.02, revenue of $84.27M beats by $25.98M TFS Financial GAAP EPS of $0.07 in-line, revenue of $79.12M beats by $9.7M Element Fleet Management Non-GAAP EPS of $0.28, revenue of $275.7M misses by $4.73M PC Connection declares $0.15 dividend Technip Energies N.V. GAAP EPS of $0.56, revenue of $1.85B explore more Westwood holdings outlines ETF growth and new mandates amid Q1 2025 earnings insights First Mid Bancshares Non-GAAP EPS of $0.96 beats by $0.02, revenue of $84.27M beats by $25.98M TFS Financial GAAP EPS of $0.07 in-line, revenue of $79.12M beats by $9.7M Element Fleet Management Non-GAAP EPS of $0.28, revenue of $275.7M misses by $4.73M PC Connection declares $0.15 dividend Technip Energies N.V. GAAP EPS of $0.56, revenue of $1.85B
